For the Inventor, By the Inventor

Enter assignee name

Luxembourg, Luxembourg

Abbvie S.a.r.l.

Calculating rank

USPTO Granted Patents = 15

% Expired Patents = 13.3

EPO Patents = 1

Forward Citations = 100

Loading Chart...

Loading Chart...

55 inventors (with patents filed for the assignee):

Philip R Kym (14 out of 59 patents)

Xueqing Wang (14 out of 41 patents)

Gregory A Gfesser (10 out of 37 patents)

4. Robert J Altenbach (9 out of 46 patents)

5. Steven Emiel Van Der Plas (9 out of 23 patents)

6. Marlon D Cowart (9 out of 59 patents)

7. Andrew Bogdan (8 out of 19 patents)

8. Nicolas Desroy (8 out of 24 patents)

9. Bo Liu (7 out of 28 patents)

10. Sachin V Patel (7 out of 22 patents)

11. Stephen N Greszler (7 out of 7 patents)

12. Ming Clinton Yeung (7 out of 30 patents)

13. Xenia Beebe Searle (7 out of 20 patents)

14. Christopher Gaëtan Housseman (6 out of 12 patents)

15. Elsa De Lemos (6 out of 6 patents)

15 patents: Sort by Forward Citations

1. 10647717 - N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2020-05-12),

2. 10604515 - Heteroaryl substituted pyridines and methods of use (2020-03-31),

3. 10428017 - Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2019-10-01),

4. 10399940 - Substituted pyrrolidines and methods of use (2019-09-03),

5. 10259810 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2019-04-16),

6. 10138227 - Heteroaryl substituted pyridines and methods of use (2018-11-27),

7. 10130622 - Compounds for treatment of cystic fibrosis (2018-11-20),

8. 10118916 - Modulators of cystic fibrosis transmembrane conductance regulator protein (2018-11-06),

9. 10047051 - Substituted pyridines and method of use (2018-08-14),

10. 9981910 - Substituted pyrrolidines and methods of use (2018-05-29),

11. 9890158 - N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use (2018-02-13),

12. 9840513 - Substituted tricyclics and method of use (2017-12-12),

13. 9796711 - [object Object] (2017-10-24),

14. 9642831 - Substituted chromanes and method of use (2017-05-09),

15. 9567322 - Substituted tetrahydropyrans and method of use (2017-02-14),

Company Overview

Abbvie S.a.r.l. is a global biopharmaceutical company headquartered in Luxembourg, specializing in the development and manufacturing of innovative therapies. The organization focuses on several key therapeutic areas, including immunology, oncology, neuroscience, and virology, striving to address complex health challenges through advanced research and technology. With a commitment to scientific excellence, Abbvie aims to enhance patient outcomes and improve quality of life across diverse populations worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

15 Patents

#58 in 244 Luxembourg

#73 in Luxembourg

#39,991 in the World

Luxembourg, Luxembourg

Abbvie S.a.r.l.

Forward Citations = 100

55 inventors:

Philip R Kym (14 out of 59 patents)

Xueqing Wang (14 out of 41 patents)

Gregory A Gfesser (10 out of 37 patents)

4. Robert J Altenbach (9 out of 46 patents)

5. Steven Emiel Van Der Plas (9 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abbvie S.a.r.l.. Retrieved from https://idiyas.com/company/abbvie-s-a-r-l

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…